PET/CT and Sentinel Node in Oral Cancer (PETNode)
Dual-time PET/CT and Sentinel Node Diagnostics Preoperatively in Patients With Oral Cancer
In this study, the investigators want to pre-operatively scan patients who do not have any clinically suspicion of metastases with an 18F-FDG-PET/CT whole body scan , where after they go to lymphoscintigraphy incl. SPECT/CT and sentinel node biopsy. Material from the oral cancer and, after permission of each patient, also normal oral tissue will be analyzed molecular-biologically. Also a blood sample will be analyzed for molecular tumor markers.
The investigators want to see if PET/CT is able to detect any signs of sub-clinically metastases. Besides, the investigators want to fusion PET/CT with SPECT/CT data from the lymphoscintigraphy study and improve our PET/CT scanning with a dual-time PET scan of the head-and-neck region.
調査の概要
状態
条件
詳細な説明
These patients are normally preoperatively sent to a CT scan of the thorax and abdomen; in this study, this CT is replaced by a wholebody PET/CT scan. Afterwards, the patients goes to sentinel node lymphoscintigraphy and then to operation.
By combining biomarkers and molecular imaging in patients with a clinically T1/T2N0M0 oral cancer, we want to characterize the tumor physiologically and correlate these physiological features to the clinical appearance of the cancer.
Aims of the study:
- can PET/CT in this patient group metastases with consequently change of treatment?
- can fusion of SPECT/CT and PET/CT with calculation of standardized uptake value (SUV) indicate, how much tumor tissue there should be in a positive sentinel node to be detected by PET?
- can dual-time PET scanning better determine lymph node metastases, than single-time PET scanning?
- correlation between SUV in PET with molecular-biological findings both in the primary tumor and in metastases
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Copenhagen、デンマーク、2100
- Dep. of Nuclear Medicine & PET
-
Copenhagen、デンマーク、2100
- Dep. of otorhinolaryngology, Head & Neck Surgery/ Rigshospitalet
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- biopsy-verified oral cancer
- over 18 years of age
Exclusion Criteria:
- under 18 years of age
- inable patients
- pregnancy
- known allergy to contrast agents
- kidney insufficiency
- other known cancer
- diabetes mellitus
- acute medical conditions such as acute infection, acute cardial or lung disease or other intercurrent diseases
研究計画
研究はどのように設計されていますか?
デザインの詳細
協力者と研究者
スポンサー
捜査官
- 主任研究者:Christine W Dümcke, Dr.、Dep. of Nuclear Medicine & PET
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。